Weill Cornell Medicine

What Weill Cornell Medicine does

Weill Cornell Medicine is a private academic medical center and constituent college of Cornell University, founded in 1898 and headquartered at 1300 York Avenue on Manhattan's Upper East Side. The institution operates across a tri-partite mission of patient care, biomedical research, and medical education, delivering clinical services through its faculty physicians at NewYork-Presbyterian/Weill Cornell Medical Center, Lower Manhattan Hospital, Queens, Brooklyn Methodist, and the Westchester Division, plus outpatient practices across Manhattan, Brooklyn, and Queens. It also operates an international medical campus in Doha, Qatar through a partnership with the Qatar Foundation. Research spans cancer, cardiovascular disease, neuroscience, infectious diseases, and precision medicine, anchored by the 18-story Belfer Research Building and supported by major federal grants from NIH, NIAID, NCI, ARPA-H, and the Department of Defense.

Revenue is generated across four streams: clinical patient care billed through insurance providers (handling 1.6 million+ annual visits), federal and private research grants, tuition from medical, doctoral, physician assistant, and master's programs, and philanthropy and development. Recent revenue diversification includes the May 2026 launches of a premium Longevity Medicine Program offering yearlong personalized preventive care and a Concierge Choice hybrid and full concierge primary care practice in Midtown Manhattan operated in partnership with Concierge Choice Physicians. The institution has cultivated a translational innovation ecosystem that has launched 43 startups from its technologies, collectively raising over $2 billion in financing, and has executed patent-protected AI/ML platforms including Nociscan for chronic low back pain (U.S. Patent #12,601,803) and the BELA system for IVF embryo assessment.

The AI/technology stack features proprietary capabilities across multiple clinical domains: AI cardiac ultrasound analysis with ~85% accuracy for peak VO2 prediction, graph neural network models for bladder cancer chemotherapy response, machine learning for preeclampsia early warning, fine-tuned large language models for radiology error detection, and computer vision for IVF embryo quality assessment. Weill Cornell Medicine also advances novel therapeutic modalities including Cornell Prime Dots (C' dots) silica nanoparticles for prostate tumors, intravesical CAR T cell therapy for bladder cancer targeting MUC16, and cell therapy platforms through the newly launched Ludwig Laboratory. With over 7,000 employees, a Fortune Best Places to Work recognition, and an ISSLS Best Paper Award 2026, the institution combines the scale and brand of a century-old academic medical center with active commercialization, technology transfer, and AI-driven diagnostic development.

Name

Weill Cornell Medicine

Legal name

Weill Cornell Medicine

Website

https://careers.weill.cornell.edu

Company type

Private

Founded year

1898

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Weill Cornell Medicine is a private academic medical center and Cornell University constituent college, founded in 1898 in New York City. It delivers patient care via NewYork-Presbyterian hospitals and affiliated practices, conducts biomedical and translational research across cancer, neuroscience, and precision medicine, and educates physicians and scientists.

Ownership category

akta.pro rank

Product category

Academic Medical Center

NAICS

General Medical and Surgical Hospitals (622110), Research and Development in the Physical, Engineering, and Life Sciences (54171), Offices of Physicians (62111)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)

akta.pro secondary industries

Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Independent Diagnostic Testing Facilities (IDTFs) & Multi-Specialty Diagnostic Centers (HLAFAKAN)

Keywords

• Academic medical center
• Clinical care services
• Biomedical research
• Medical education
• Graduate medical training

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Patient Care: Revenue from patient care services at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Lower Manhattan Hospital, NewYork-Presbyterian Queens, and outpatient practices throughout Manhattan, Brooklyn, and Queens. Handles over 1.6 million patient visits annually.
2. Research Grants and Funding: Federal and private research grants including NIH funding (e.g., $9.8M NIH grant for long COVID research, $5.2M ARPA-H grant for lymphatic disease diagnostics).
3. Educational Programs: Tuition and fees from medical, doctoral, and master's programs. Weill Cornell Graduate School and medical education programs.
4. Development and Philanthropy: Donations and fundraising from individuals and organizations supporting medical research and institutional priorities.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Weill Cornell Medicine is a private academic medical center that delivers specialty and primary patient care through NewYork-Presbyterian hospitals and affiliated outpatient practices, conducts biomedical and translational research across cancer, cardiovascular disease, neuroscience, and infectious diseases, and educates physicians and scientists through its medical school, graduate programs, and residency training. It also commercializes discoveries through technology transfer, startups, and clinical research partnerships.

Product overview

Weill Cornell Medicine operates as an academic medical center offering a diverse portfolio of clinical services, research programs, and specialized healthcare offerings. The institution provides traditional patient care through primary and specialty practices throughout New York City, including a new hybrid Concierge Choice primary care program. Its Longevity Medicine Program offers personalized preventive healthcare integrating genetics, nutrition, and wellness monitoring. Research capabilities include novel cancer therapeutics such as Cornell Prime Dots nanoparticles and intravesical CAR T cell therapy for bladder cancer, as well as diagnostic platforms like the Nociscan MRI spectroscopy system for chronic back pain. The institution also develops AI-powered diagnostic tools for conditions including heart failure, bladder cancer treatment response prediction, IVF embryo quality assessment, and preeclampsia early warning.

Differentiator

Problem solved

Functional benefit

Products and services

• Longevity Medicine Program
• Concierge Choice Primary Care Practice
• Obstetrics and Gynecology Practices
• Nociscan Diagnostic Platform
• LANTERN Diagnostic Toolbox for Lymphatic Disease
• Intravesical CAR T Cell Therapy for Bladder Cancer
• Cornell Prime Dots (C' Dots) Nanoparticle Therapy

Named customers7 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability14 records

Feature11 records

Partnerships

19 partnerships are on record, tiered core and minor.

• Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer CentercoreStrategic or Co-development Partner · 26 June 2026Intravesical CAR T therapy development for bladder cancer targeting MUC16 protein, offering potential bladder-sparing alternative to complete organ removal.
• Tiziana Life SciencesminorStrategic or Co-development Partner · 17 June 2026Phase 2a INFORM-MS clinical trial evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis across multiple U.S. clinical sites.
• Ruhr University BochumcoreStrategic or Co-development Partner · 15 June 2026Development of fluorescence imaging-based technique for measuring scramblase protein activity at single-molecule resolution, published in Nature Structural & Molecular Biology.
• Cornell Duffield College of EngineeringcoreStrategic or Co-development Partner · 15 June 2026Cornell Prime dots (C' dots) nanoparticles developed for prostate tumor therapy that kill cancer cells and convert cold tumor microenvironments to hot, achieving complete remissions in preclinical studies.
• CytoDyncoreStrategic or Co-development Partner · 11 June 2026SALIENT-AD Phase 2a clinical study evaluating leronlimab for Alzheimer's disease, expanding CytoDyn's leronlimab development program beyond oncology into neurodegenerative disease.
• BostonGenecoreStrategic or Co-development Partner · 8 June 2026Six abstracts at EHA2026 Congress showcasing AI and multiomics platforms for blood cancer treatment optimization, integrating molecular profiling for risk assessment and CAR-T therapy resistance prediction.
• Cornell Duffield College of EngineeringcoreStrategic or Co-development Partner · 1 June 2026Engineering Innovations in Medicine initiative with up to $7.25M investment over three years to advance data-driven medicine through interdisciplinary collaboration at intersection of engineering, data science, and medicine.
• Concierge Choice PhysicianscoreChannel Partner/ Reseller/ Distributor · 28 May 2026Hybrid and full concierge care program launched at Midtown Clinical Care Center offering expanded physician availability and preventive wellness services through membership-based options.
• Exero MedicalminorStrategic or Co-development Partner · 11 May 2026222-patient multicenter pivotal study of xBar monitoring system for early detection of colorectal surgery complications, presented at ASCRS Annual Scientific Meeting 2026.
• AclarioncoreStrategic or Co-development Partner · 5 May 2026Nociscan diagnostic platform deployed in prospective randomized controlled trial evaluating lumbar microdiscectomy surgery outcomes over 2-year period led by Dr. Roger Härtl. Second agreement with Weill Cornell for Nociscan technology.
• AclarioncoreStrategic or Co-development Partner · 5 May 2026Second commercial agreement for Nociscan technology deployment in prospective randomized controlled trial evaluating bone marrow aspirate stem cell concentrate dosing.
• BioInnovate Conference ecosystemcoreStrategic or Co-development Partner · 23 April 2026Annual conference bringing together scientists, startup founders, and industry partners to discuss translating scientific discoveries into scalable healthcare solutions. Weill Cornell Medicine innovation ecosystem has launched 43 startups raising over $2 billion.
• Cristian Rivera FoundationminorStrategic or Co-development Partner · 10 March 2026Foundation supporting DIPG and pediatric brain tumor research, funding clinical trials at Weill Cornell Medicine where three children responded positively to CAR-T cell therapy.
• Rev: Ithaca Startup WorksminorStrategic or Co-development Partner · 26 February 2026MedTech track partnership in 10-week Prototyping Hardware Accelerator supporting entrepreneurs developing physical product concepts from ideation to proof-of-concept.
• Singular GenomicscoreStrategic or Co-development Partner · 25 February 2026SPOT-Met program - 1,000-tumor colorectal cancer initiative leveraging G4X platform, described as perhaps the world's largest colorectal cancer spatial multiomics initiative.
• iRegene TherapeuticscoreStrategic or Co-development Partner · 23 February 2026iRegene dosed first U.S. patient in Phase IIa trial of NouvNeu001 for Parkinson's disease at Weill Cornell Medical Center. Leverages AI + Chemical Induction platform for neurodegenerative disease treatments.
• Nautilus Biotechnology and The Michael J. Fox FoundationcoreStrategic or Co-development Partner · 29 January 2026$1.6 million research collaboration to study alpha-synuclein protein and Parkinson's disease using Nautilus' single-molecule proteomics platform and Weill Cornell Medicine-Qatar's expertise in alpha-synuclein biology.
• Memorial Sloan Kettering Cancer Center, Georgia Tech, and Stanford MedicinecoreStrategic or Co-development Partner · 20 January 2026LANTERN project - $5.2M ARPA-H award to develop comprehensive diagnostic approach for lymphatic disease using nanotechnology, AI, and genetic analysis.
• Immunai Inc.coreStrategic or Co-development Partner · 12 January 2026Grand Collaboration Initiative for Single-Cell Immune Profiling with selected research projects across autoimmune kidney disease, T-cell redirection therapy in multiple myeloma, neoadjuvant immunotherapy in NSCLC, and immunotherapy resistance in gastric cancer.

Scale indicators10 records

Recent moves9 records

Expansion highlights7 records

Direct peers

• NYU Langone Health: Major New York City academic medical center affiliated with NYU, providing quaternary clinical care, biomedical research, and medical education. Directly comparable to Weill Cornell Medicine in mission, NYC footprint, research output, and patient mix.
• UCSF Health: University of California, San Francisco's academic medical center with a major research enterprise and top NIH funding rankings. Comparable breadth of clinical specialties, biomedical research output, and public-mission alignment.
• Mount Sinai Health System: Large NYC academic health system encompassing the Icahn School of Medicine at Mount Sinai. Comparable to Weill Cornell Medicine in scope of clinical specialties, NIH-funded research portfolio, and graduate medical education programs.
• Mass General Brigham: Harvard-affiliated integrated academic health system anchored by Massachusetts General Hospital and Brigham and Women's Hospital. Closest peer in research intensity, total NIH funding, and clinical complexity, and a frequent head-to-head comparison for Weill Cornell.
• Penn Medicine (University of Pennsylvania Health System): University of Pennsylvania's integrated academic medical center combining the Perelman School of Medicine with a multi-hospital system. Comparable in size, research funding, and biomedical innovation pipeline including gene therapy and CAR-T programs.
• Stanford Medicine: Stanford University's academic medical enterprise combining Stanford Hospital, Lucile Packard Children's Hospital, and the medical school. Comparable translational research engine, biotech spinout activity, and partnership with engineering (Bioengineering, Computer Science) paralleling Weill Cornell's Cornell Duffield collaboration.
• Johns Hopkins Medicine: Top-ranked US academic medical center integrating Johns Hopkins University School of Medicine with a large hospital system. Comparable scale, research output, and prestige; competes for the same NIH funding pool, top faculty, and complex patient referrals.
• Columbia University Irving Medical Center: Columbia University's academic medical center located in upper Manhattan, providing clinical care, biomedical research, and medical education. Directly competes with Weill Cornell Medicine for patients, faculty, and grant funding in the NYC market.

Broad incumbents

• NewYork-Presbyterian Hospital: Weill Cornell Medicine's primary clinical affiliate and one of the largest hospital systems in the US. Overlapping clinical enterprise, physician faculty, and research infrastructure, though organized as a multi-hospital delivery system rather than a single medical school.
• Memorial Sloan Kettering Cancer Center: Tri-institutional research partner of Weill Cornell Medicine and the leading US cancer specialty hospital. Comparable in research intensity and oncology focus, with overlapping faculty and joint programs including the Meyer Cancer Center and Ludwig Laboratory for Cell Therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/weillcornell
• Facebookfacebook.com/WeillCornellMedicine
• LinkedInlinkedin.com/company/weillcornellmedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Weill Cornell Medicine